Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines

Pharmaceutical Research

Volumn 16, Issue 8, 1999, Pages 1199-1205

  Madani, Soraya ^a   Paine, Mary F ^a   Lewis, Lydia ^a   Thummel, Kenneth E ^a   Shen, Danny D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP2D6; First pass metabolism; Human intestine; Human liver; In vitro in vivo scaling; Metoprolol oxidation

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; METOPROLOL;

ARTICLE; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION;

ADRENERGIC BETA-ANTAGONISTS; CYTOCHROME P-450 CYP2D6; HUMANS; INTESTINAL MUCOSA; INTESTINE, SMALL; KINETICS; METABOLIC CLEARANCE RATE; METOPROLOL; MICROSOMES, LIVER; OXIDATION-REDUCTION;

EID: 0032815783     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018989211864     Document Type: Article

References (18)

1. 1. I. de Wazier, P. H. Cugnenc, C. S. Yang, J. P. Leroux, and P. H. Beaune. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394 (1990).
2. 2. P. Du Souich, H. Maurice, and L. Héroux. Contribution of the small intestine to the first pass uptake and systemic clearance of propranolol in rabbits. Drug Metab. Dispos. 23:279-84 (1995).
3. 3. T. Prueksaritanont, L. M. Dwyer, and A. E. Cribb. (+) Bufuralol 1′-hydroxylation activity in human and rhesus monkey intestine and liver. Biochem. Pharmacol. 50:1521-1525 (1995).
4. 4. T. Prucksaritanont, L. M. Gorham, J. H. Hochman, L. O. Tran, and K. P. Vyas. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in caco-2 cells. Drug Metab. Dispos. 24:634-642 (1996).
5. 5. Y. K. Tam. Individual variation in first-pass metabolism. Clin. Pharmacokin. 25:300-325 (1993).
6. 6. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423 (1994).
7. 7. M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel. Characterization of inter-and intra-intestinal differences in human CYP3A-dependent metabolism. J. Phamacol. Exp. Ther. 283:1552-1562 ( 1997).
8. 8. S. Snyder, M. J. Cook, E. S. Nasset, L. R. Karhausen, G. P. Howells, and I. H. Tipton. Report of the task group on reference man, Pergamon Press, Oxford, 1975, pp. 134-144.
9. 9. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. I. Randal. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
10. 10. T. Omura and R. Sato. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification and properties. J. Biol. Chem. 239:2379-2385 (1964).
11. 11. M. Kim, L. K. Roskos, D. D. Shen, A. C. Eddy, and W. L. Nelson. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab. Dispos. 21:309-317 (1992).
12. 12. P. Klippert, P. Borm, and J. Noodhoek. Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetics data - Correlation with the in vivo data using mucosal blood flow. Biochem. Pharmacol. 31:2545-2548 (1988).
13. 13. L. Hultén, J. Lindhagen, and O. Lundgren. Sympathetic nervous control of intramural blood flow in the feline and human intestines. Gastroenterology 72:41-48 (1977).
14. 14. K. A. Johansson, L. Appelgren, K. O. Borg, and R. Elofsson. Binding of two beta-adrenoceptor antagonists, alprenolol and H93/26 to human serum proteins. Acta Pharm. Suec. 11:333-346 (1974).
15. 15. H. Hoensch, C. H. Woo, S. B. Raffin, and R. Schmid. Oxidative metabolism of foreign compounds in rat small intestine. Cellular localization and dependency on dietary iron. Gastroenterology 70:1063-1070 (1976).
16. 16. M. S. Lennard, G. T. Tucker, J. H. Silas, S. Freestone, L. E. Ramsay, and H. F. Woods. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin. Pharmacol. Ther. 34:732-737 (1983).
17. 17. P. R. Gwilt, S. Comer, P. R. Chaturvedi, and D. H. Waters. The influence of diffusional barriers on presystemic gut elimination. Drug Metab. Dispos. 16:521-526 (1988).
18. 18. V. J. Wacher, L. Salphati, and L. Z. Benet. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Del. Rev. 20:99-112 (1996).